Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23571670 | 0.81 | NPC1 (0.33) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL798511 | 0.81 | MCHR1 (0.45) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL22479121 | 0.79 | NPC1 (0.33) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4790793 | 0.77 | NPC1 (0.59) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL29304400 | 0.77 | KDM4E (0.41) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL29136817 | 0.77 | MAP3K5 (0.38) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL23197729 | 0.77 | APP (0.38) | NPC1RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL18389508 | 0.77 | MCHR1 (0.43) | MCHR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL24737348 | 0.75 | KDM4E (0.40) | NPC1RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL29302392 | 0.75 | KDM4E (0.43) | NPC1RAB9AKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-8575360-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | MCHR1 118/4885NPC1 2641/4885RAB9A 1945/4885 |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | MCHR1 1901/4885NPC1 256/4885RAB9A 2840/4885 |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | MCHR1 2/4885NPC1 1550/4885RAB9A 1603/4885 |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | MCHR1 2325/4885NPC1 3221/4885RAB9A 2556/4885 |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | ARG1, COL14A1, HPGDS | MCHR1 4383/4885NPC1 4760/4885RAB9A 4707/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | MCHR1 745/4885NPC1 1577/4885RAB9A 669/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | MCHR1 2325/4885NPC1 3221/4885RAB9A 2556/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | MCHR1 1718/4885NPC1 4173/4885RAB9A 996/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | MCHR1 3966/4885NPC1 952/4885RAB9A 3054/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MCHR1 1657/4885NPC1 565/4885RAB9A 473/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | MCHR1 1598/4885NPC1 4078/4885RAB9A 1035/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | MCHR1 1657/4885NPC1 565/4885RAB9A 473/4885 |
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DPYD, TYMP, TYMS | MCHR1 4783/4885NPC1 1344/4885RAB9A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.